Cargando…

Population Immunity to Pre-Omicron and Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Variants in US States and Counties Through 1 December 2021

BACKGROUND: Both severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) vaccination contribute to population-level immunity against SARS-CoV-2. This study estimated the immunological exposure and effective protection against future SARS-CoV-2 i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klaassen, Fayette, Chitwood, Melanie H, Cohen, Ted, Pitzer, Virginia E, Russi, Marcus, Swartwood, Nicole A, Salomon, Joshua A, Menzies, Nicolas A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214178/ https://www.ncbi.nlm.nih.gov/pubmed/35717642 http://dx.doi.org/10.1093/cid/ciac438

Ejemplares similares

Population immunity to pre-Omicron and Omicron SARS-CoV-2 variants in US states and counties through December 1, 2021
por: Klaassen, Fayette, et al.
Publicado: (2022)

Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022
por: Klaassen, Fayette, et al.
Publicado: (2023)

Changes in population immunity against infection and severe disease from SARS-CoV-2 Omicron variants in the United States between December 2021 and November 2022
por: Klaassen, Fayette, et al.
Publicado: (2022)

Reconstructing the course of the COVID-19 epidemic over 2020 for US states and counties: results of a Bayesian evidence synthesis model
por: Chitwood, Melanie H., et al.
Publicado: (2021)

Reconstructing the course of the COVID-19 epidemic over 2020 for US states and counties: Results of a Bayesian evidence synthesis model
por: Chitwood, Melanie H., et al.
Publicado: (2022)

Association Between Cycle Threshold Value and Vaccination Status Among Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Cases in Ontario, Canada, in December 2021
por: Ravindran, Saranyah, et al.
Publicado: (2023)

Rapid increase in Omicron infections in England during December 2021: REACT-1 study
por: Elliott, Paul, et al.
Publicado: (2022)

Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization
por: Morris, C Paul, et al.
Publicado: (2022)

Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021
por: Brandal, Lin T., et al.
Publicado: (2021)

Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021
por: Espenhain, Laura, et al.
Publicado: (2021)

US County-Level COVID-19 Vaccine Uptake and Rates of Omicron Cases and Deaths
por: McLaughlin, John M, et al.
Publicado: (2022)

Trends in Cases, Hospitalizations, and Mortality Related to the Omicron BA.4/BA.5 Subvariants in South Africa
por: Jassat, Waasila, et al.
Publicado: (2022)

Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Delta and Omicron Infection and Infectiousness Within Households in the Netherlands Between July 2021 and August 2022
por: Hoeve, Christina E, et al.
Publicado: (2023)

An Imported Case of BA.2 Lineage of Omicron Variant COVID-19 — Guangdong Province, China, December 28, 2021
por: Guo, Qianfang, et al.
Publicado: (2022)

Tracking the progressive spread of the SARS-CoV-2 Omicron variant in Italy, December 2021 to January 2022
por: Stefanelli, Paola, et al.
Publicado: (2022)

The impact of changes in diagnostic testing practices on estimates of COVID-19 transmission in the United States
por: Pitzer, Virginia E., et al.
Publicado: (2020)

Description of Hospitalizations due to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Based on Vaccination Status
por: Moffa, Matthew A, et al.
Publicado: (2022)

Trends, Mechanisms, and Racial/Ethnic Differences of Tuberculosis Incidence in the US-Born Population Aged 50 Years or Older in the United States
por: Kim, Sun, et al.
Publicado: (2021)

Clinical Characteristics and Outcomes of Immunocompromised Patients With Coronavirus Disease 2019 Caused by the Omicron Variant: A Prospective, Observational Study
por: Malahe, S Reshwan K, et al.
Publicado: (2022)

Effectiveness of COVID-19 Vaccines Over Time Prior to Omicron Emergence in Ontario, Canada: Test-Negative Design Study
por: Chung, Hannah, et al.
Publicado: (2022)

Evaluation of Bebtelovimab for Treatment of Covid-19 During the SARS-CoV-2 Omicron Variant Era
por: McCreary, Erin K, et al.
Publicado: (2022)

Assessment of the Effectiveness of Omicron Transmission Mitigation Strategies for European Universities Using an Agent-Based Network Model
por: Lasser, Jana, et al.
Publicado: (2022)

Serial Intervals for SARS-CoV-2 Omicron and Delta Variants, Belgium, November 19–December 31, 2021
por: Kremer, Cécile, et al.
Publicado: (2022)

Omicron-Associated Changes in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Symptoms in the United Kingdom
por: Vihta, Karina-Doris, et al.
Publicado: (2022)

Fifteen days in December: capture and analysis of Omicron-related travel restrictions
por: Schermerhorn, Jordan, et al.
Publicado: (2022)

Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch
por: Razonable, Raymund R, et al.
Publicado: (2022)

Visualizing and assessing US county-level COVID19 vulnerability
por: Cahill, Gina, et al.
Publicado: (2021)

Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients
por: Gliga, Smaranda, et al.
Publicado: (2022)

Genomic Variability of SARS-CoV-2 Omicron Variant Circulating in the Russian Federation during Early December 2021 and Late January 2022
por: Chernyaeva, Ekaterina N., et al.
Publicado: (2022)

The First Two Imported Cases of SARS-CoV-2 Omicron Variant — Tianjin Municipality, China, December 13, 2021
por: Tan, Zhaolin, et al.
Publicado: (2022)

SARS-CoV-2 B.1.1.529 (Omicron) Variant — United States, December 1–8, 2021
Publicado: (2021)

COVID-19 Vaccine Effectiveness during a Prison Outbreak when Omicron was the Dominant Circulating Variant—Zambia, December 2021
por: Simwanza, John, et al.
Publicado: (2022)

Investigation of Blood Plasma Viral Nucleocapsid Antigen as a Marker of Active Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Infection
por: Damhorst, Gregory L, et al.
Publicado: (2023)

SARS-CoV-2 antigen rapid tests and universal screening for COVID-19 Omicron variant among hospitalized children
por: Kam, Kai-Qian, et al.
Publicado: (2023)

Immunity of Heterologously and Homologously Boosted or Convalescent Individuals Against Omicron BA.1, BA.2, and BA.4/5 Variants
por: Jäger, Michael, et al.
Publicado: (2023)

Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron Variants
por: Junker, Daniel, et al.
Publicado: (2022)

An Imported Case and an Infected Close Contact of the Omicron Variant of SARS-CoV-2 — Guangdong Province, China, December 13, 2021
por: Li, Kuibiao, et al.
Publicado: (2022)

Investigation of a SARS-CoV-2 B.1.1.529 (Omicron) Variant Cluster — Nebraska, November–December 2021
por: Jansen, Lauren, et al.
Publicado: (2021)

Effectiveness of MRNA booster vaccine among healthcare workers in New York City during the Omicron surge, December 2021 to January 2022
por: Robilotti, Elizabeth V., et al.
Publicado: (2022)

Temporal, age, and geographical variation in vaccine efficacy against infection by the Delta and Omicron variants in the community in France, December 2021 to March 2022
por: Blanquart, François, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qggprecjav3d48bt6qinjkqkhn